The Myxo File by Nalini M. Rajamannan, MD reveals the lack of response by the Center for Device and Radiologic Health for the ongoing sale and surgical implants of non-approved FDA heart devices in United States Citizens

CHICAGO, Jan. 14, 2013 /CNW/ - The FDA 510(k) process is a complex process allowing Companies to apply or to not apply for a new 510(k) application. The Myxo File: Part I and Part II  just released through Kindle Direct Publishing will provide documents from the FDA compliance review and the letters sent by members of Congress and the White House including the letter from The Honorable Senator John McCain from Arizona on behalf of Illinois Constituents and the White House communications to get help for the patients.

(Photo: http://photos.prnewswire.com/prnh/20130114/MM42113)

"The patients will understand what happened during their open heart procedure to repair their heart valve between 2006-2008."  says author Nalini Marie Rajamannan M. D. Sacred Heart Cardiology, Chicago IL.

"With the Myxo File Part I and Part II, the biographical story and the documents providing the 3-Agency Chart from the FDA, US Patent office and the United States Securities and Exchange Commission websites to help to explain the events that happened during the clinical study to test a new invention in the hearts of her patients during open heart surgery.

"My book will help to educate the citizens of the United States of America to ask the important questions prior to open heart surgery as to whether the device that will be used to repair their valve is FDA registered, cleared, approved, investigational or none of the above."

Rajamannan was inspired to create the Myxo File when the documents she accumulated over a five year quest to get the information regarding the patients ended with a search of the US SEC website. The Filings indicate the chronology of disclosures of the medical device to investors. "With my electronic file and 3-Agency Chart, you still have to take action, and ask your physicians whether you are about to be included in a clinical study to test devices prior to FDA clearance, but at least the citizens of the United States will have a guidepost to help them ask the right questions.

The FDA is the oversight branch of the US federal government to protect the citizens of this country.

Nalini M. Rajamannan is a cardiologist at Sacred Heart Cardiology, Sheboygan, WI, and Chicago, IL. She is the CEO of ConcieValve LLC, and recently published her textbook on Cardiac Valvular Medicine, Springer Publisher.

SOURCE: ConcieValve LLC

[email protected]
312-498-9496